Mannkind MNKD
by Anonymous Questions | February 26, 2015 9:35 pm
Could the good Dr. comment on Mannkind, now that it’s Affrezza insulin inhaler is now on the market. I’m of the opinion that this could be a game changer, particularly for those who just can’t stand the thought of daily needles.
Source URL: https://www.stockgumshoe.com/2015/02/microblog-mannkind-mnkd/
Afrezza is a rapid acting insulin–ie, for meal times for diabetics. Most people also use a basal (long-acting insulin) as well, which is only available as an injection. Granted, this would cut down to one-two injections per day, versus at every meal. So, the daily needle has not gone away, although the development of an inhaled long acting insulin might be a possibility. Also, this would be limited to those patients who do not have asthma, COPD, etc.
Nobody wants it, niche product at absolute best. The needles are so small now days in pens that there is nothing to be afraid of. Hate MNKD, Alfred will go down the tubes on this one UNLESS……… he can license the delivery technology, that is the true key. Not Insulin.